Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema

Acta Ophthalmologica

Volumn 86, Issue 4, 2008, Pages 365-371

  Soliman, Wael ^a,b,c   Vinten, Martin ^a   Sander, Birgit ^a   Soliman, Kamell Abd El Naser ^b   Yehya, Sameer ^b   Rahman, Mohamed Saad Abdel ^b   Larsen, Michael ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b ASSIUT UNIVERSITY   (Egypt)

^c GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Bevacizumab; Diabetic macular oedema; Optical coherence tomography; Vessel diameter

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BLOOD VESSEL DIAMETER; CASE STUDY; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG EFFICACY; FEMALE; FIBROSIS; HUMAN; MALE; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETINA BLOOD VESSEL; RETINA FOVEA; RETINA MACULA LUTEA; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; VASOCONSTRICTION; VISUAL ACUITY; CELL DIVISION; CLINICAL TRIAL; DRUG EFFECT; INJECTION; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; RETINA MACULA EDEMA; TREATMENT OUTCOME; VITREOUS BODY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CELL DIVISION; DIABETIC RETINOPATHY; FEMALE; FOVEA CENTRALIS; HUMANS; INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINAL VESSELS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VITREOUS BODY;

EID: 47649085946     PISSN: 1755375X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0420.2007.01057.x     Document Type: Article

References (22)

1. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H et al. (2007): Primary intravitreal bevacizumab (Avastin) for diabetic macular oedema: Results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 114: 743-750.
2. Avery RL, Pearlman J, Pieramici DJ et al. (2006b): Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113: 1695-1715.
3. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA & Giust MJ (2006a): Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113: 363-372.
4. Bresnick GH (1983): Diabetic maculopathy. A critical review highlighting diffuse macular oedema. Ophthalmology 90: 1301-1317.
5. Campochiaro PA (2004): Reduction of diabetic macular oedema by oral administration of the kinase inhibitor PKC412. Invest Ophthalmol Vis Sci 45: 922-931.
6. Chun DW, Heier JS, Topping TM, Duker JS & Bankert JM (2006): A pilot study of multiple intravitreal injections of ranibizumab in patients with centre-involving clinically significant diabetic macular oedema. Ophthalmology 113: 1706-1712.
7. Cunningham ET Jr, Adamis AP, Altaweel M et al. (2005): A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular oedema. Ophthalmology 112: 1747-1757.
8. Early Treatment Diabetic Retinopathy Study Research Group (1985): Photocoagulation for diabetic macular oedema. Early Treatment Diabetic Retinopathy Study Report No. 1. Arch Ophthalmol 103: 1796-1806.
9. Edelman JL, Lutz D & Castro MR (2005): Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res 80: 249-258.
10. Gottfredsdottir MS, Stefansson E, Jonasson F & Gislason I (1993): Retinal vasoconstriction after laser treatment for diabetic macular oedema. Am J Ophthalmol 115: 64-67.
11. Haritoglou C, Kook D, Neubauer A et al. (2006): Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular oedema. Retina 26: 999-1005.
12. Ishida S, Usui T, Yamashiro K et al. (2003): VEGF164 is pro-inflammatory in the diabetic retina. Invest Ophthalmol Vis Sci 44: 2155-2162.
13. Klein R, Klein BE & Moss SE (1984): Visual impairment in diabetes. Ophthalmology 91: 1-9.
14. Larsen M, Colmorn LB, Bonnelycke M, Kaaja R, Immonen I, Sander B & Loukovaara S (2005): Retinal artery and vein diameters during pregnancy in diabetic women. Invest Ophthalmol Vis Sci 46: 709-713.
15. Lee CM & Olk RJ (1991): Modified grid laser photocoagulation for diffuse diabetic macular oedema. Longterm visual results. Ophthalmology 98: 1594-1602.
16. Marshall J (2005): The role of bevacizumab as first-line therapy for colon cancer. Semin Oncol 32 (Suppl.): 43-47.
17. Nguyen QD, Shah SM, Van AE, Sung JU, Vitale S & Campochiaro PA (2004): Supplemental oxygen improves diabetic maAular oedema: a pilot study. Invest Ophthalmol Vis Sci 45: 617-624.
18. Nguyen QD, Tatlipinar S, Shah SM et al. (2006): Vascular endothelial growth factor is a critical stimulus for diabetic macular oedema. Am J Ophthalmol 142: 961-969.
19. Ozaki H, Hayashi H, Vinores SA, Moromizato Y, Campochiaro PA & Oshima K (1997): Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Exp Eye Res 64: 505-517.
20. Pedersen R, Soliman W, Lund-Andersen H & Larsen M (2007): Treatment of choroidal neovascularization using intravitreal bevacizumab. Acta Ophthalmol Scand 85: 526-533.
21. Strom C, Sander B, Klemp K, Aiello LP, Lund-Andersen H & Larsen M (2005): Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular oedema. Invest Ophthalmol Vis Sci 46: 3855-3858.
22. Vinten M, Larsen M, Lund-Andersen H, Sander B & la Cour M (2007): Short-term effects of intravitreal triamcinolone on retinal vascular leakage and trunk vessel diameters in diabetic macular oedema. Acta Ophthalmol Scand 85: 21-26.